Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

Authors: Lepor N.E.; Gross S.B.¹; Daley W.L.; Samuels B.A.; Rizzo M.J.; Luko S.P.; Hickey A.; Buchbinder N.A.; Naqvi T.Z.

Source: The American Journal of Cardiology, Volume 86, Number 1, 1 July 2000 , pp. 107-110(4)

Publisher: Elsevier

Language: English

Document Type: Short communication

DOI: 10.1016/S0002-9149(00)00840-7

Affiliations: 1: aHeart Center of Los Angeles, , Los Angeles, California, USA

Links for this article

http://www.ingentaconnect.com/els/00029149/2000/00000086/00000001/art00840
http://openurl.ingenta.com/content?genre=article&issn=0002-9149&volume=86&issue=1&spage=107&epage=110
http://dx.doi.org/10.1016/S0002-9149(00)00840-7